11 recruiting, 10 completed, 2 not yet recruiting, 1 enrolling by invitation. 26 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Recruiting 11, Completed 10, Not yet recruiting 2, Enrolling by invitation 1, Suspended 1, Terminated 1 |
| Phase 2 | 10 | Recruiting 5, Completed 4, Enrolling by invitation 1 |
Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 60 | 2026-12-01 | 2026-10-21 |
| Recovery Management Checkup Scalability and Sustainability Hybrid Experiment Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters), Recovery Management Checkups (RMC) delivered by staff under the research team (RMC by research staff) - Substance Use Disorder (SUD), Opioid Use Disorders | Phase 3 | Not yet recruiting | Chestnut Health Systems | 600 | 2026-11-02 | 2026-10-14 |
| Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya Cystine, Positively Smoke Free, Placebo - HIV, Tobacco Use | Phase 3 | Not yet recruiting | University of Chicago | 300 | 2026-07-31 | 2026-07-30 |
| Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) Semaglutide, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | VA Office of Research and Development | 622 | 2026-07-28 | 2026-09-21 |
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms Psilocybin (high dose), Psilocybin (low dose) - Alcohol Use Disorder, Depressive Sympotoms | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nīmes | 172 | 2026-06-30 | 2026-07-01 |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA - Post Traumatic Stress Disorder, Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | VA Office of Research and Development | 80 | 2026-05-18 | 2026-06-02 |
| A Study of Brenipatide in Participants With Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-16 | 2026-10-08 |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-15 | 2026-10-07 |
| Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder ketone supplement "D-beta-hydroxybutryric acid and R-1,3 butanediol" 12g of ketones,, magnetic resonance imaging session, Placebo beverage - Alcohol Use Disorder, Alcohol Withdrawal | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 30 | 2025-08-01 | 2025-09-15 |
| Electronic Harm Reduction Treatment for Alcohol eHaRT-A - Alcohol Use Disorder, Harm Reduction | Phase 3 | Recruiting | University of Washington | 160 | 2025-01-20 | 2025-07-08 |
| Emergency Department-Initiated Medications for Alcohol Use Disorder Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview - Alcohol Use Disorder | Phase 3 | Recruiting | Yale University | 240 | 2024-08-17 | 2026-07-21 |
| Effects of Ketone Supplementation on Acute Alcohol Withdrawal Kenetik; Ketone Concentrate, Isocaloric dextrose placebo - Alcohol Use Disorder, Alcohol Withdrawal | Phase 2 / Phase 3 | Enrolling by invitation | University of Pennsylvania | 50 | 2024-03-11 | 2026-04-06 |
| The Effects of Sex Hormones and Alcohol on Sleep Ethanol, Saline - Alcohol Use Disorder | Phase 3 | Suspended | Ohio State University | 130 | 2024-01-08 | 2026-09-28 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep Lemborexant 10 mg, Naltrexone - Alcohol Use Disorder | Phase 3 | Completed | Baylor College of Medicine | 8 | 2023-02-09 | 2026-03-24 |
| Integrated Digital Intervention for Alcohol Use Disorder Mobile health application, Medical Management - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | Quit Genius | 242 | 2023-01-01 | 2025-11-20 |
| Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder Oxytocin nasal spray, Naltrexone Pill, Placebo - Alcohol Use Disorder, Alcoholism | Phase 2 / Phase 3 | Completed | Central Institute of Mental Health, Mannheim | 62 | 2021-12-02 | 2024-03-29 |
| Ketone Ester Intervention in Alcohol Use Disorder Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", Isocaloric dextrose placebo, Alcohol drinks - Alcohol Drinking, Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 20 | 2021-04-05 | 2026-02-09 |
| Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms AD04 (ondansetron), Matching placebo, Companion Diagnostic for Genetic Testing - Alcohol Use Disorder | Phase 3 | Completed | Adial Pharmaceuticals | 302 | 2020-02-01 | 2024-04-17 |
| Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Dutasteride Capsules, Placebo Capsules - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | UConn Health | 180 | 2019-10-15 | 2025-05-09 |
Showing 20 of 26. Sign in to see all of them.
Alcoholism (26) · Ketosis (3) · Alcoholic Intoxication (2) · Drinking Behavior (2) · Opioid-Related Disorders (2) · Stress Disorders, Post-Traumatic (2) · Substance-Related Disorders (2) · Alcohol Drinking (1) · Cognitive Dysfunction (1) · Color Vision Defects (1) · Emergencies (1) · Harm Reduction (1) · Marijuana Abuse (1) · Tobacco Use (1) · Tobacco Use Cessation (1)
Alcohol-Related Disorders (26) · Chemically-Induced Disorders (26) · Mental Disorders (26) · Substance-Related Disorders (24) · Behavior (5) · Acid-Base Imbalance (3) · Acidosis (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Narcotic-Related Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Stress Disorders, Traumatic (2) · Trauma and Stressor Related Disorders (2) · Cognition Disorders (1) · Cone Dystrophy (1)
Ethanol (3) · Naltrexone (3) · Zonisamide (2) · vivitrol (2) · Alcoholic Beverages (1) · Cannabidiol (1) · Cystine (1) · Dutasteride (1) · Gabapentin (1) · Genetic Testing (1) · Ketones (1) · Magnetic Resonance Spectroscopy (1) · Ondansetron (1) · Practice Management, Medical (1) · Pregabalin (1)
University of Pennsylvania (4) · VA Office of Research and Development (3) · Eli Lilly and Company (2) · Adial Pharmaceuticals (1) · Baylor College of Medicine (1) · Central Institute of Mental Health, Mannheim (1) · Centre Hospitalier Universitaire de Nīmes (1) · Chestnut Health Systems (1) · Ohio State University (1) · Oregon Health and Science University (1) · Quit Genius (1) · UConn Health (1) · University of Chicago (1) · University of Colorado, Denver (1) · University of Maryland, Baltimore (1)
United States (22) · Germany (3) · Belgium (2) · China (2) · Japan (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Bulgaria (1) · Canada (1) · Croatia (1) · Estonia (1) · Finland (1) · France (1) · Kenya (1)
Corinde E Wiers, Ph.D. (2) · Corinde Wiers, Ph.D. (2) · Albert Arias, MD (1) · Albert J Arias, MD (1) · Amandine Luquiens (1) · Brian Hicks, PhD (1) · David W. Oslin, MD (1) · Erica M. Eaton, PhD (1) · Jonathan Covault, MD, PhD (1) · Kathryn Hawk, MD, MHS (1) · Kent Hutchison, PhD (1) · Michael L Dennis, PhD (1) · Morris Bell (1)
PMID 15850502, PMID 19032530, PMID 22439295, PMID 27920321, PMID 28061017, PMID 29336496, PMID 29379114, PMID 29540927, PMID 30538599, PMID 34291990, PMID 35410938, PMID 38113919, PMID 40342086, PMID 40483726
2025 (3), K01AA030053 (1), P50AA027055 (1), R00AA026892 (1), R01AA024466 (1), R01AA024760 (1), R01AA029606 (1), R01AA030308 (1), R01AA030568 (1), R01AA031570 (1), R01CA288235 (1), R03DA034718 (1), R21AA031337 (1), RM1DA064526 (1), U10DA015815 (1)